Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

EU Clinical Investigations Taipei 2018

253 views

Published on

EU Medical Device Clinical Trial environment in 2018

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

EU Clinical Investigations Taipei 2018

  1. 1. EU Clinical Investigations Dr Annet Muetstege Medical Device Clinical Trial Symposium Taipei 05-SEP-2018
  2. 2. Key definitions 1/2 • Clinical data: MEDDEV 2.7/1: The safety and/or performance information that is generated from the clinical use of a device. • Clinical Use: MEDDEV 2.7/1: Use of a medical device in or on living human subjects. Note: Includes use of a medical device that does not have direct patient contact. • Sufficient clinical evidence: MEDDEV 2.7/1: An amount and quality of clinical evidence to guarantee the scientific validity of the conclusions. • State of the art: MEDDEV 2.7/1: Information relating to the medical condition managed with the device and its natural course, benchmark devices, other devices and medical alternatives available to the target population. ACS-Clinical Evaluation & Investigation | TFDA 20180905 2
  3. 3. Key definitions 2/2 • Clinical investigation: ISO 14155 - systematic investigation in one or more human subjects, undertaken to assess the safety or performance of a medical device NOTE “Clinical trial” or “clinical study” are synonymous with “clinical investigation” • Premarket Study: MEDDEV 2.7/3 - Clinical investigation conducted with: a) Non-CE marked devices, b) CE marked devices used outside the intended use(s) covered by the CE marking. • Postmarket/ PMCF Study: MEDDEV 2.12/2 - A study carried out following the CE marking of a device and intended to answer specific questions relating to clinical safety or performance (i.e. residual risks) of a device when used in accordance with its approved labelling. ACS-Clinical Evaluation & Investigation | TFDA 20180905 3
  4. 4. Clinical Evidence gaps? • Premarket ➢First round clinical evaluation indicates there is insufficient qualitative data to verify that the device meets the ER’s ➢Classical Clinical Investigation • Postmarket ➢Clinical evaluation indicates there are uncertainties or unanswered questions regarding safety or performance ➢Post Market Clinical Followup ACS-Clinical Evaluation & Investigation | TFDA 20180905 4
  5. 5. Clinical Evidence gaps? • Premarket Clinical Investigation (MEDDEV 2.7/1): ➢ Implants and high-risk devices and devices that extend the intended purpose are likely to require clinical investigation data, but also ➢ New technologies, and class I, IIa, and IIb devices with clinical evidence gaps ACS-Clinical Evaluation & Investigation | TFDA 20180905 5
  6. 6. Clinical Evidence gaps? • Postmarket Clinical Follow-Up (MEDDEV 2.12/2): ➢ The manufacturer should aim at including all patients in PMCF studies for a device: • that carries significant risks, or • for rare diseases ➢ Other cases include: • premarket follow-up time scales and the expected life of the product, • where CE marking was based on equivalence ACS-Clinical Evaluation & Investigation | TFDA 20180905 6
  7. 7. EU Clinical Study Regulatory • Premarket ➢ MDD, Declaration of Helsinki, ISO 14155, MEDDEV 2.7/3 • Postmarket ➢ MDD, Declaration of Helsinki, ISO 14155, MEDDEV 2.12-1 and 2.12/2 • Local requirements ➢ Different per country • MDR ➢ More attention clinical investigation ➢ ISO 14155, ➢ Includes all Post-market studies ACS-Clinical Evaluation & Investigation | TFDA 20180905 7 0 100 200 300 400 MDD MDR Count "investigation"
  8. 8. Clinical Investigation requirements • CIP/ protocol • IB or equivalent documentation • Informed Consent Form and any other written information to be provided to subjects • Procedures for recruiting subjects and advertising materials, if any • Qualifications of the principal investigator and team • Study insurance • Applicable regulatory approvals • AE documentation & reporting • Progress and final reports ACS-Clinical Evaluation & Investigation | TFDA 20180905 8
  9. 9. Clinical Investigation - endpoints • Safety ➢ Adverse Events ➢ Type and number of AE’s • Performance ➢ Depends on device involved • Patient benefit ➢ Mortality, morbidity, QoL • Timing/ duration of effect(s) ➢ Patient follow-up ACS-Clinical Evaluation & Investigation | TFDA 20180905 9
  10. 10. Clinical Investigation - design • RCT or single arm; single or multicenter; interventional or observational; short or long term patient follow-up? ➢ What is the clinical evidence gap? ➢ State of the Art/ Standard of Care -> International differences? ➢ New treatment or first of its kind? ➢ Pre- or Postmarket study? ➢ Standards? ➢ Scope -> Multiple use of clinical data? ACS-Clinical Evaluation & Investigation | TFDA 20180905 10
  11. 11. Conclusion • EU - higher clinical evidence demands ➢ Definitions more comprehensive ➢ Clinical evaluation requires more clinical data throughout the Product Life Cycle ➢ Regulatory environment becoming more strict for medical device Pre- and Postmarket studies ➢ Clinical studies are expensive and people are not guinea pigs -> even more careful development of clinical studies is needed ACS-Clinical Evaluation & Investigation | TFDA 20180905 11
  12. 12. Questions? info@appliedclinicalservices.com ACS-Clinical Evaluation & Investigation | TFDA 20180905 12

×